| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
1 company
Dennis Slamon last filed a Form 4 in March 2024, as Director at BMRN. Dennis Slamon's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
At the last filing, the largest reported position was 31,299 shares of BMRN. The BMRN filings lean toward selling, a net 6,396 shares.
Dennis Slamon has 10 Form 4 filings on record from June 2016 to March 2024, all as Director at Biomarin Pharmaceutical (BMRN), 2016–2024.
The 18 reported transactions were 8 stock awards, 6 open-market sales, 2 option or other derivative awards and 1 option exercise, plus smaller numbers of other types.
Counted by filing, the open-market trades come to no purchases and 1 sale worth about $501K.
The only open-market sale was 6,396 shares of BMRN at an average $78.33 on February 28, 2022, about $501K. Twelve months later BMRN was up 27%.
Shares as reported in the last Form 4 for each company; the most recent is from March 2024. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Feb 28, 2022 | BMRN Biomarin Pharmaceutical Inc | Director | Sell | 6,396 | $78.33 | $501,013.27 | -22.8% | -3.8% | +27.5% |